Kiora Pharmaceuticals (NASDAQ: KPRX) announced preclinical data demonstrating that KIO-300, a novel ion channel modulator, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
KIO-300 is the active pharmaceutical ingredient of KIO-301, which is currently in Phase 2 clinical development for vision restoration in patients with gene mutation-agnostic retinitis pigmentosa. The new data suggests that KIO-300 may have broader therapeutic applications beyond retinal disease, potentially addressing unmet needs in epilepsy treatment.
The ex vivo model used brain slices from patients with temporal lobe epilepsy, a common and often drug-resistant form of epilepsy. Treatment with KIO-300 resulted in a significant reduction in epileptiform activity, indicating its potential to modulate neuronal excitability. This is particularly important because approximately one-third of epilepsy patients do not respond to existing antiseizure medications, highlighting the need for novel mechanisms of action.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease, targeting critical pathways underlying retinal degeneration. The company's pipeline includes KIO-301 for retinitis pigmentosa and other inherited retinal diseases, and KIO-104 for macular edema due to retinal inflammation. The company expects to post information on its website, www.kiorapharma.com, and social media accounts that could be relevant to investors.
The implications of these findings are significant. If KIO-300 proves effective in further preclinical and clinical studies, it could offer a new treatment option for patients with drug-resistant epilepsy. Moreover, the ability to repurpose a compound already in clinical development for another indication could accelerate the path to regulatory approval and reduce development costs. The company's ion channel modulator platform may also have potential in other neurological disorders characterized by abnormal neuronal excitability.
Forward-looking statements in the press release include expectations regarding the company's ability to execute on development efforts and the potential for pipeline expansion. However, these statements involve risks and uncertainties that may cause results to differ materially, including the ability to conduct clinical trials on a timely basis and market conditions. The full announcement, including downloadable images and bios, is available through the provided link.
